Improvement Of Blood Glucose Control With Artificial Pancreas In Coronavirus Disease Covid-19

This paper aims to evaluate the use of artificial pancreas in patients with severe coronavirus disease 2019 (COVID-19) who have difficulty regulating their blood glucose (BG) levels. In this study, a total of 1048 arterial blood glucose readings were obtained, 181 under artificial and 867 under normal therapy. Compared to the usual therapy (16.021.5 mg/dl at 133 days), the artificial pancreas' daily HGI was reduced (p = 0.0387). There was no significant difference in the rate of parenteral sugar administration at each BG measurement point (p0.0001). Insulin delivery rate during normal therapy was substantially lower than that during BG measurements under the artificial Pancras (p=0.0001). The rate of enteral glucose administration at BG test points was significantly lower under artificial Pancreas compared to normal therapy (p 0.0001). Patients with severe COVD-19 may have a better prognosis with better BG control with the artificial pancreas. Further research is necessary to determine whether employing an artificial Pancreas to improve blood glucose control can improve the prognoses of critically ill patients.